期刊文献+

痰瘀同治方对鸡胚绒毛尿囊膜血管新生的影响 被引量:2

Effect of formula of Tan Yu Tong Zhi on angiogenesis in chicken embryo allantois membrane
原文传递
导出
摘要 目的:探讨痰瘀同治方对鸡胚绒毛尿囊膜血管新生的影响。方法:将8日龄鸡胚制备鸡胚绒毛尿囊膜(CAM)模型随机分为4组:空白血清组,大、中、小剂量含药血清组(加入各组相应的含药血清)。培养3d后观察各组对CAM模型标本形态及血管新生数量的影响。结果:大剂量含药血清组粗大血管及细小分支迅速增多,血管网络清晰,呈叶脉样,放射性生长,血管新生数量明显高于空白血清组(P<0.01),中剂量及小剂量含药血清组与空白血清组比较有一定优势,但无统计学意义。结论:痰瘀同治方可明显促进鸡胚绒毛尿囊膜血管新生。 Objective: To observe the effect of formula of Tan Yu Tong Zhi for promoting angiogenesis on chofio-auantoic membrance (CAM). Methods: Prepare model of CAM, use medicated serum of the formula of Tan Yu Tong Zhi on CAM, The breeding eggs were divided into 4 groups: high-dose, medium-dose, low-dose and blank control serum. Growth shape of chicken embryo and vessels count of CAM model in each group were observed after 3 days. Results: The vasculature growth was rapidly in the medication group with high-dose. The primary and secondary vessels were promoted in the groups with high-dose, which was significantly different from normal serum group (P〈0.01). There was no significant difference between the medium-dose and normal serum group. Conclusion: The fomula of Tan Yu Tong Zhi showed obvious promotion effects on CAM angiogenesis.
作者 朱盛 刘建勋
出处 《中华中医药杂志》 CAS CSCD 北大核心 2012年第5期1292-1294,共3页 China Journal of Traditional Chinese Medicine and Pharmacy
基金 重大新药创制(No.2009ZX09303-003 No.2009ZX09301-005-2-6)~~
关键词 含药血清 血管新生 鸡胚绒毛尿囊膜模型 Medicated serum Angiogenesis CAM
  • 相关文献

参考文献4

二级参考文献22

  • 1王世军,孙静,张栋,郭继龙,简隆磊,刘铠.鸡胚尿囊膜血管生长的特点及观测方法[J].生物医学工程研究,2004,23(1):38-40. 被引量:16
  • 2张暋,梁东辉,李小敏,曾昭龙,钱学贤,尹炳生.冠心病痰瘀辨证分型与血清脂蛋白动态平衡关系的研究[J].中国中西医结合杂志,1995,15(1):9-12. 被引量:81
  • 3杜立杰,王学东,胡大一.炎症与动脉粥样硬化[J].中国心血管杂志,2006,11(1):62-65. 被引量:16
  • 4刘容,周建英.肿瘤血管生成的实验研究方法[J].国际呼吸杂志,2007,27(5):375-378. 被引量:4
  • 5任立群,王金凤,李永梅,张秀云,李广生.同型半胱氨酸对血管平滑肌细胞基质金属蛋白酶1及金属蛋白酶组织抑制剂1的影响(英文)[J].中国组织工程研究与临床康复,2007,11(27):5455-5457. 被引量:2
  • 6Mackness B, MacknessMI, Arrol S, et al. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification [ J ]. Febs Lett, 1998,423 : 57-60.
  • 7Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? [J]. Arterioscler Thromb Vasc Biol, 2001,21 (9) : 1451- 1457.
  • 8Mackness B, Durrington P, McElduff P, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study [ J ]. Circulation, 2003, 107 : 2775 -2779.
  • 9Behowski J, Wojcicka G, Jamroz A. Effect of 3-hydroxy-3- methylglutaryl-eoenzymeA reductase inhibitors (statins) on tissue paraoxonase 1 and plasma platelet activating factor acetylhydrolase activities [ J ] . J Cardiovasc Pharmacol, 2004, 43(1): 121-127.
  • 10Deakin S, Leviev I, Guemier S, James RW. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2 [ J]. Arterioscler Thromb Vasc Biol, 2003, 23 ( 11 ) : 2 083-2089.

共引文献54

同被引文献40

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部